The purpose of this study was to integrate US and clinicopathological characteristics to predict whether patients with HER2-positive breast cancer undergoing NACT would achieve pCR, as US allows for non-invasive and dynamic observation of tumor changes throughout preoperative NACT to allow for timely changes in treatment regimen in case of poor treatment outcome. The gene discussed is ERBB2; the disease is breast cancer.